Current Pathobiology Reports

, Volume 6, Issue 4, pp 225–231 | Cite as

Nanotechnology Enabled Inhalation of Bio-therapeutics for Pulmonary Diseases: Design Considerations and Challenges

  • N. JoshiEmail author
Nanoparticle-based Drug Delivery (R Banerjee, Section Editor)
Part of the following topical collections:
  1. Nanoparticle-based Drug Delivery


Purpose of Review

This review aims to critically discuss design considerations for the development of nanoparticle-based formulations for inhalation delivery of bio-therapeutics in pulmonary diseases. We will also discuss the challenges towards clinical translation of this approach, highlighting the directions for future research.

Recent Findings

Nanotechnology-based inhalation delivery of bio-therapeutics in pulmonary diseases can potentially overcome the shortcomings of clinically used parenteral route. Exploration of inhalable nanoparticles for delivery of bio-therapeutics in pulmonary diseases is still at an early stage. While most of these approaches have been developed for the delivery of nucleic acids, a few have focused on delivering monoclonal antibodies and proteins. However, multiple challenges need to be addressed for successful translation of this approach.


We summarize the design considerations and challenges that may help in creating a roadmap for the development of clinically translatable nanoparticle-based inhalable formulations of bio-therapeutics for pulmonary diseases.


Nanoparticles Bio-therapeutics Aerosol Drug delivery Pulmonary 


Compliance with Ethical Standards

Conflict of Interest

The author declares that there is no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L. Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017.
  2. 2.
    Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. BMJ. 2016;352:i859. Scholar
  3. 3.
    Pavord ID. Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141:1983–91. Scholar
  4. 4.
    McCracken JL, Tripple JW, Calhoun WJ. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol. 2016;16:375–82. Scholar
  5. 5.
    Fellner RC, Terryah ST, Tarran R. Inhaled protein/peptide-based therapies for respiratory disease. Mol Cell Pediatr. 2016;3:16. Scholar
  6. 6.
    Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release. 2014;196:344–54. Scholar
  7. 7.
    •• Desoubeaux G, Reichert JM, Sleeman M, et al. Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs. 2016;8:999–1009. This comprehensive report from a meeting emphasizes why inhalation delivery of monoclonal antibodies in pulmonary diseases deserves further investigation.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Matucci A, Nencini F, Pratesi S, Maggi E, Vultaggio A. An overview on safety of monoclonal antibodies. Curr Opin Allergy Clin Immunol. 2016;16:576–81. Scholar
  9. 9.
    Niebecker R, Kloft C. Safety of therapeutic monoclonal antibodies. Curr Drug Saf. 2010;5:275–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–38. Scholar
  11. 11.
    Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF. Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study. Drugs - real world outcomes. 2016;3:369–81. Scholar
  12. 12.
    Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet (London, England). 2007;370:1422–31. Scholar
  13. 13.
    Lightwood D, Tservistas M, Zehentleitner M, Sarkar K, Turner A, Bracher M, et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am J Respir Crit Care Med. 2018;198:610–9. Scholar
  14. 14.
    Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother. 2015;59:4162–72. Scholar
  15. 15.
    Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999;160:1023–7. Scholar
  16. 16.
    Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille JF, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs. 2014;6:1347–55. Scholar
  17. 17.
    Rajapaksa AE, Ho JJ, Qi A, Bischof R, Nguyen TH, Tate M, et al. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir Res. 2014;15:60. Scholar
  18. 18.
    Cortez-Jugo C, Qi A, Rajapaksa A, Friend JR, Yeo LY. Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics. 2015;9:52603. Scholar
  19. 19.
    Koussoroplis SJ, Paulissen G, Tyteca D, Goldansaz H, Todoroff J, Barilly C, et al. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J Control Release. 2014;187:91–100. Scholar
  20. 20.
    Duncan GA, Jung J, Hanes J, Suk JS. The mucus barrier to inhaled gene therapy. Mol Ther. 2016;24:2043–53. Scholar
  21. 21.
    Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv. 2017;3:e1601556. Scholar
  22. 22.
    Huang X, Chisholm J, Zhuang J, Xiao Y, Duncan G, Chen X, et al. Protein nanocages that penetrate airway mucus and tumor tissue. Proc Natl Acad Sci. 2017;114:E6595–602. Scholar
  23. 23.
    Joshi N, Kaur S, Banerjee R. Advances in sub-micron particle based aerosol strategies for efficient systemic delivery of therapeutic agents. Curr Pharm Des. 2016;22:2470–80.CrossRefPubMedGoogle Scholar
  24. 24.
    Joshi N. Can nanotechnology hit the spot in aerosol-based drug delivery for lung disorders? Ther Deliv. 2018;9:233–6. Scholar
  25. 25.
    • Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SRP. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm. 2014;11:1808–22. This study demonstrates the the developemnet of a nanoparticle paltfordm for siRNA delivery to lung epithelium.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Xu C-X, Jere D, Jin H, Chang SH, Chung YS, Shin JY, et al. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med. 2008;178:60–73. Scholar
  27. 27.
    Fernández Fernández E, Santos-Carballal B, de Santi C, Ramsey JM, MacLoughlin R, Cryan S-A, Greene CM. Biopolymer-based nanoparticles for cystic fibrosis lung gene therapy studies. Mater (Basel, Switzerland) 2018:11. Doi:
  28. 28.
    Mottais A, Le Gall T, Sibiril Y, Ravel J, Laurent V, D’Arbonneau F, Montier T. Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties. Biosci Rep 2017:37. Doi:
  29. 29.
    • Halwani R, Sultana Shaik A, Ratemi E, Afzal S, Kenana R, Al-Muhsen S, et al. A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma. Exp Mol Med. 2016;48:e262. This study demonstrates the development of a nanoparticle platform for delivery of a monoclonal antibody in asthma.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–18. Scholar
  31. 31.
    Omlor AJ, Nguyen J, Bals R, Dinh QT. Nanotechnology in respiratory medicine. Respir Res. 2015;16:64. Scholar
  32. 32.
    Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem Sci. 2017;8:63–77. Scholar
  33. 33.
    Schwendener RA, Schott H. Liposome formulations of hydrophobic drugs. Methods Mol Biol. 2010;605:129–38. Scholar
  34. 34.
    Sahana DK, Mittal G, Bhardwaj V, Kumar MNVR. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci. 2008;97:1530–42. Scholar
  35. 35.
    Sousa F, Castro P, Fonte P, Kennedy PJ, Neves-Petersen MT, Sarmento B. Nanoparticles for the delivery of therapeutic antibodies: dogma or promising strategy? Expert Opin Drug Deliv. 2017;14:1163–76. Scholar
  36. 36.
    Haggag YA, Faheem AM. Evaluation of nano spray drying as a method for drying and formulation of therapeutic peptides and proteins. Front Pharmacol. 2015;6:140. Scholar
  37. 37.
    Di Stasio E, De Cristofaro R. The effect of shear stress on protein conformation: physical forces operating on biochemical systems: the case of von Willebrand factor. Biophys Chem. 2010;153:1–8. Scholar
  38. 38.
    Hertel SP, Winter G, Friess W. Protein stability in pulmonary drug delivery via nebulization. Adv Drug Deliv Rev. 2015;93:79–94. Scholar
  39. 39.
    Respaud R, Vecellio L, Diot P, Heuzé-Vourc’h N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12:1027–39. Scholar
  40. 40.
    Poptsova MS, Il’icheva IA, Nechipurenko DY, Panchenko LA, Khodikov MV, Oparina NY, et al. Non-random DNA fragmentation in next-generation sequencing. Sci Rep. 2014;4:4532. Scholar
  41. 41.
    Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PNV, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144:233–41. Scholar
  42. 42.
    Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–9. Scholar
  43. 43.
    Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release. 2003;86:131–44.CrossRefPubMedGoogle Scholar
  44. 44.
    Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002;19:425–98.CrossRefPubMedGoogle Scholar
  45. 45.
    Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002;99:12001–5. Scholar
  46. 46.
    Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm. 2012;424:98–106. Scholar
  47. 47.
    Chadha TS, Chattopadhyay S, Venkataraman C, Biswas P. Study of the charge distribution on liposome particles aerosolized by air-jet atomization. J Aerosol Med Pulm Drug Deliv. 2012;25:355–64. Scholar
  48. 48.
    Chattopadhyay S. Aerosol generation using nanometer liposome suspensions for pulmonary drug delivery applications. J Liposome Res. 2013;23:255–67. Scholar
  49. 49.
    Iyer R, Hsia CCW, Nguyen KT. Nano-therapeutics for the lung: state-of-the-art and future perspectives. Curr Pharm Des. 2015;21:5233–44.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release. 2005;102:373–81. Scholar
  51. 51.
    Joshi N, Shanmugam T, Kaviratna A, Banerjee R. Proapoptotic lipid nanovesicles: synergism with paclitaxel in human lung adenocarcinoma A549 cells. J Control Release. 2011;156:413–20. Scholar
  52. 52.
    Joshi N, Shirsath N, Singh A, Joshi KS, Banerjee R. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep. 2014;4:7085. Scholar
  53. 53.
    Sethi M, Sukumar R, Karve S, Werner ME, Wang EC, Moore DT, et al. Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. Nanoscale. 2014;6:2321–7. Scholar
  54. 54.
    Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the paclitaxel in-stent controlled elution study (PISCES). J Am Coll Cardiol. 2005;46:253–60. Scholar
  55. 55.
    Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, Khoshayand MR, Atyabi F, Sabzevari A, et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci. 2013;50:341–52. Scholar
  56. 56.
    Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61:158–71. Scholar
  57. 57.
    Porsio B, Craparo EF, Mauro N, Giammona G, Cavallaro G. Mucus and cell-penetrating nanoparticles embedded in nano-into-micro formulations for pulmonary delivery of Ivacaftor in patients with cystic fibrosis. ACS Appl Mater Interfaces. 2018;10:165–81. Scholar
  58. 58.
    Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release. 2005;109:299–316. Scholar
  59. 59.
    Selby LI, Cortez-Jugo CM, Such GK, Johnston APR. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9.
  60. 60.
    Ma D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale. 2014;6:6415–25. Scholar
  61. 61.
    Chu Z, Miu K, Lung P, Zhang S, Zhao S, Chang H-C, et al. Rapid endosomal escape of prickly nanodiamonds: implications for gene delivery. Sci Rep. 2015;5:11661. Scholar
  62. 62.
    Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31:653–8. Scholar
  63. 63.
    Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 2008;295:L400–11. Scholar
  64. 64.
    Li JJ, Muralikrishnan S, Ng C-T, Yung L-YL, Bay B-H. Nanoparticle-induced pulmonary toxicity. Exp Biol Med (Maywood). 2010;235:1025–33. Scholar
  65. 65.
    Li JG, Li QN, Xu JY, Cai XQ, Liu RL, Li YJ, et al. The pulmonary toxicity of multi-wall carbon nanotubes in mice 30 and 60 days after inhalation exposure. J Nanosci Nanotechnol. 2009;9:1384–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol. 2006;215:100–8. Scholar
  67. 67.
    Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:521–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Donaldson K, Murphy F, Schinwald A, Duffin R, Poland CA. Identifying the pulmonary hazard of high aspect ratio nanoparticles to enable their safety-by-design. Nanomedicine (Lond). 2011;6:143–56. Scholar
  69. 69.
    Shah AR, Hagawane T, Kshirsagar N, Banerjee R. Surface-active drug loaded lipopolymeric nanohybrid aerosol therapy: potential non-invasive way to mitigate lipopolysaccharide mediated inflammation in murine lungs. RSC Adv. 2015;5:9683–94. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Engineering in Medicine, Department of MedicineBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations